Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Form 8.3 - The Vanguard Group, Inc.: Aviva plc
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook


DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the

Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook
Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2024 and Initial 2025 Outlook


DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an increase of 8% over the

STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025
STAAR Surgical to Host Fourth Quarter and Fiscal Year 2024 Earnings Conference Call and Webcast on February 19, 2025


STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release

Simulations Plus Supported Development of Every FDA-Approved Drug in 2024
Simulations Plus Supported Development of Every FDA-Approved Drug in 2024


Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical

Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update


Novocure (NASDAQ: NVCR) today reported preliminary unaudited financial and operational results for the quarter and full year ended December 31, 2024. Novocure is a global oncology company working

Interface Unveils First-Ever Carbon Negative Rubber Flooring Prototype
Interface Unveils First-Ever Carbon Negative Rubber Flooring Prototype


Interface, Inc. (NASDAQ: TILE), the global flooring solutions company and leader in sustainability, today revealed a first-of-its-kind carbon negative nora® rubber flooring prototype that stores

Notice of AGM
Notice of AGM
Notice of AGM
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
United Bankshares, Inc. Completes Acquisition of Piedmont Bancorp, Inc.
United Bankshares, Inc. Completes Acquisition of Piedmont Bancorp, Inc.


United Bankshares, Inc. (“United”) (NASDAQ: UBSI), parent company of United Bank, today announced the completion of its acquisition of Atlanta-based Piedmont Bancorp, Inc. (“Piedmont”), parent

Essex Announces Release and Conference Call Dates for Its Fourth Quarter 2024 Earnings
Essex Announces Release and Conference Call Dates for Its Fourth Quarter 2024 Earnings


Essex Property Trust, Inc. (NYSE:ESS) announced today that it plans to release its fourth quarter 2024 earnings after the market closes on Tuesday, February 4, 2025. A conference call with senior

First Business Bank Announces Fourth Quarter 2024 Earnings Conference Call
First Business Bank Announces Fourth Quarter 2024 Earnings Conference Call


First Business Financial Services, Inc. (the “Company” or “First Business Bank”) (Nasdaq:FBIZ) invites participation in a conference call to discuss the Company’s financial and operating

Mettler-Toledo International Inc. to Host Fourth Quarter 2024 Earnings Conference Call
Mettler-Toledo International Inc. to Host Fourth Quarter 2024 Earnings Conference Call


Mettler-Toledo International Inc. (NYSE: MTD) announced it will release its fourth quarter 2024 financial results after the market close on Thursday, February 6, 2025. The Company will host a

AI Solutions for Visually Impaired, AI Search and AI Agents Win ISG Startup Challenges
AI Solutions for Visually Impaired, AI Search and AI Agents Win ISG Startup Challenges


AI-powered solutions for addressing visual impairments, optimizing brands for AI search and creating AI agents won the ISG Startup Challenges at recent events in Paris, Dallas and London hosted by

ISG Study Says Need for Flexibility is Driving Demand for AI-Powered Payroll Platforms
ISG Study Says Need for Flexibility is Driving Demand for AI-Powered Payroll Platforms


New business models, a rapidly expanding remote workforce and increasing demand for real-time, automated systems powered by AI are driving payroll transformation, according to a new series of

Morgan Stanley Appoints 173 New Managing Directors
Morgan Stanley Appoints 173 New Managing Directors


Morgan Stanley has announced the appointment of 173 Managing Directors. The new Managing Directors are:

Andrea Alberti

Jon LeBoutillier

Andrew Arena

Ben L. Lee

Emma Atkins

WisdomTree Reports Monthly Metrics for December 2024
WisdomTree Reports Monthly Metrics for December 2024


WisdomTree, Inc. (NYSE: WT), a global financial innovator, today released monthly metrics for December 2024, including assets under management (AUM) and flow data by asset class.



Monthly

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder
Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder


Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose

CI Financial Announces Filing and Mailing of Circular for Special Meeting to Approve Plan of Arrangement with Mubadala Capital
CI Financial Announces Filing and Mailing of Circular for Special Meeting to Approve Plan of Arrangement with Mubadala Capital


CI Financial Corp. (“CI” or the “Corporation”) (TSX: CIX) today announced the commencement of the mailing of its management information circular and related shareholder meeting materials for the

Astronics Corporation Announces Preliminary Unaudited Revenue for Fourth Quarter 2024 and Initiates Revenue Guidance for 2025
Astronics Corporation Announces Preliminary Unaudited Revenue for Fourth Quarter 2024 and Initiates Revenue Guidance for 2025


Astronics Corporation (Nasdaq: ATRO), a leading provider of advanced technologies for global aerospace, defense and other mission critical industries, announced its fourth quarter 2024 preliminary

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer


Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer


Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination

Helmerich & Payne, Inc. Announces Fiscal First Quarter 2025 Conference Call and Webcast
Helmerich & Payne, Inc. Announces Fiscal First Quarter 2025 Conference Call and Webcast


In conjunction with Helmerich & Payne, Inc.’s (NYSE: HP) fiscal first quarter 2025 earnings release, you are invited to listen to its conference call on Thursday, February 06, 2025, at 11:00 a.m

Bankwell Financial Group, Inc. Announces Date of Fourth Quarter Earnings Conference Call
Bankwell Financial Group, Inc. Announces Date of Fourth Quarter Earnings Conference Call


Bankwell Financial Group, Inc. (NASDAQ: BWFG), the holding company for Bankwell Bank, today announced that it will issue its earnings release for the quarter ended December 31, 2024, on Wednesday